heart racing tirzepatide Lilly's Tirzepatide Reduced Heart Failure and Obesity Symptoms in Phase 3 Trial Tirzepatide cuts heart failure risk

Statistical modeling indicates that over one-third of these protein shifts drive disease resolution through biological pathways independent of weight reduction [17]

Lancet Oncol 20(7):e378-e389, 2019

Clinical evaluations were conducted during the first follow-up visit, which took place between December 7 and 21, 2024

GLP-1 receptor agonists have rapidly risen to become one of the defining breakthroughs in metabolic medicine

Each delivery method has trade-offs in terms of convenience, bioavailability, and consistency of results

Tirzepatide also resulted in a marked reduction in the sleep apnoea-specific hypoxic burden, which comprises frequency, duration and depth of oxygen desaturation related to sleep events, and is considered to better reflect the risk of cardiovascular complications and death from sleep apnoea